Metamizole: Current status of the safety and efficacy
Metamizole is a nonsteroidal anti-inflammatory drug, with analgesic, antipyretic, spasmolytic, and weak anti-inflammatory properties. The analgesic effect of metamizole seems to be based on the inhibition of cyclooxygenase enzyme activity and stimulation of cannabinoid receptors. Its use is still co...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Srpsko lekarsko drustvo
2018-01-01
|
| Series: | Hospital Pharmacology |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2018/2334-94921803694M.pdf |
| _version_ | 1819087441863114752 |
|---|---|
| author | Miljković Milijana N. Rančić Nemanja K. Simić Radoje M. Stamenković Dušica M. Dragojević-Simić Viktorija M. |
| author_facet | Miljković Milijana N. Rančić Nemanja K. Simić Radoje M. Stamenković Dušica M. Dragojević-Simić Viktorija M. |
| author_sort | Miljković Milijana N. |
| collection | DOAJ |
| description | Metamizole is a nonsteroidal anti-inflammatory drug, with analgesic, antipyretic, spasmolytic, and weak anti-inflammatory properties. The analgesic effect of metamizole seems to be based on the inhibition of cyclooxygenase enzyme activity and stimulation of cannabinoid receptors. Its use is still controversial, mainly due to agranulocytosis, metamizole-induced serious adverse reaction. While in many countries it is withdrawn from the market, in some countries metamizole is available as a medication prescribed for strictly defined indications, while in the others like Mexico, Brazil and China it can be obtained as an Over-The-Counter drug. The most common adverse effects of metamizole are the skin and subcutaneous tissue disorders. Metamizole appears to be of similar efficacy to analgesics which are frequently used in the treatment of moderate to severe postoperative pain. |
| first_indexed | 2024-12-21T21:36:12Z |
| format | Article |
| id | doaj.art-4f47717c91f44b9c9b58c701f5bed9ed |
| institution | Directory Open Access Journal |
| issn | 2334-9492 2334-9492 |
| language | English |
| last_indexed | 2024-12-21T21:36:12Z |
| publishDate | 2018-01-01 |
| publisher | Srpsko lekarsko drustvo |
| record_format | Article |
| series | Hospital Pharmacology |
| spelling | doaj.art-4f47717c91f44b9c9b58c701f5bed9ed2022-12-21T18:49:29ZengSrpsko lekarsko drustvoHospital Pharmacology2334-94922334-94922018-01-01536947042334-94921803694MMetamizole: Current status of the safety and efficacyMiljković Milijana N.0Rančić Nemanja K.1Simić Radoje M.2Stamenković Dušica M.3Dragojević-Simić Viktorija M.4University of Defence, Medical Faculty Military Medical Academy, Centre for Clinical Pharmacology, BelgradeUniversity of Defence, Medical Faculty Military Medical Academy, Centre for Clinical Pharmacology, BelgradeUniversity of Belgrade, Institute for Mother and Child Health Care of Serbia 'Dr. Vukan Cupic', Medical School, Department for Plastic Surgery, BelgradeUniversity of Defence, Medical Faculty Military Medical Academy, Clinic for Anesthesiology and Critical Care, BelgradeUniversity of Defence, Medical Faculty Military Medical Academy, Centre for Clinical Pharmacology, BelgradeMetamizole is a nonsteroidal anti-inflammatory drug, with analgesic, antipyretic, spasmolytic, and weak anti-inflammatory properties. The analgesic effect of metamizole seems to be based on the inhibition of cyclooxygenase enzyme activity and stimulation of cannabinoid receptors. Its use is still controversial, mainly due to agranulocytosis, metamizole-induced serious adverse reaction. While in many countries it is withdrawn from the market, in some countries metamizole is available as a medication prescribed for strictly defined indications, while in the others like Mexico, Brazil and China it can be obtained as an Over-The-Counter drug. The most common adverse effects of metamizole are the skin and subcutaneous tissue disorders. Metamizole appears to be of similar efficacy to analgesics which are frequently used in the treatment of moderate to severe postoperative pain.https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2018/2334-94921803694M.pdfmetamizoleadverse drug reactionagranulocytosispainefficacy |
| spellingShingle | Miljković Milijana N. Rančić Nemanja K. Simić Radoje M. Stamenković Dušica M. Dragojević-Simić Viktorija M. Metamizole: Current status of the safety and efficacy Hospital Pharmacology metamizole adverse drug reaction agranulocytosis pain efficacy |
| title | Metamizole: Current status of the safety and efficacy |
| title_full | Metamizole: Current status of the safety and efficacy |
| title_fullStr | Metamizole: Current status of the safety and efficacy |
| title_full_unstemmed | Metamizole: Current status of the safety and efficacy |
| title_short | Metamizole: Current status of the safety and efficacy |
| title_sort | metamizole current status of the safety and efficacy |
| topic | metamizole adverse drug reaction agranulocytosis pain efficacy |
| url | https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2018/2334-94921803694M.pdf |
| work_keys_str_mv | AT miljkovicmilijanan metamizolecurrentstatusofthesafetyandefficacy AT rancicnemanjak metamizolecurrentstatusofthesafetyandefficacy AT simicradojem metamizolecurrentstatusofthesafetyandefficacy AT stamenkovicdusicam metamizolecurrentstatusofthesafetyandefficacy AT dragojevicsimicviktorijam metamizolecurrentstatusofthesafetyandefficacy |